コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e transcriptase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor.
2 vir-ritonavir when each is combined with two nucleoside reverse transcriptase inhibitors.
3 s of initial antiretroviral therapy with two nucleoside reverse transcriptase inhibitors.
4 cleoside reverse transcriptase inhibitors or nucleoside reverse transcriptase inhibitors.
5 se Inhibitors (PI) with the same backbone of Nucleoside Reverse Transcriptase Inhibitors.
6 the one previously described for the IAS non-nucleoside reverse transcriptase inhibitors.
7 ients received 400 mg RAL twice daily plus 2 nucleoside reverse transcriptase inhibitors.
8 utation renders viral resistance to multiple nucleoside reverse transcriptase inhibitors.
9 a historical trial of single- versus double-nucleoside reverse-transcriptase inhibitors.
10 sisting of efavirenz, nelfinavir, and 1 or 2 nucleoside reverse-transcriptase inhibitors.
11 in 57 children previously treated with only nucleoside reverse-transcriptase inhibitors.
12 nantiomers of two pyrimidine-based HIV-1 non-nucleoside reverse transcriptase inhibitors, 1 (MC1501)
13 ed protease inhibitor-based regimens (vs non-nucleoside reverse transcriptase inhibitor; 1.17, 1.00-1
14 % in a control test using 37 known HIV-1 non-nucleoside reverse transcriptase inhibitors; 10 out of 3
15 tiretroviral therapy (HAART), 189 (47%) dual nucleoside reverse transcriptase inhibitors (2NRTI), and
16 ithout 12-weekly CD4 counts and to receive 2 nucleoside reverse transcriptase inhibitors (2NRTI, main
17 e more common for NNRTIs (5.4%), followed by nucleoside reverse transcriptase inhibitors (3.0%) and p
18 lve (14%) included mutations associated with nucleoside reverse-transcriptase inhibitors, 4 (5%) incl
19 tide reverse transcriptase inhibitors, 2 non-nucleoside reverse transcriptase inhibitors, 7 protease
20 ere regulated by cognate nucleotides and non-nucleoside reverse transcriptase inhibitors, a major cla
21 as defined by failure of three subclasses of nucleoside reverse transcriptase inhibitors, a non-nucle
22 he alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors, a number of
23 in a randomized, placebo-controlled trial of nucleoside reverse transcriptase inhibitors (ACTG 152) w
26 ranscriptase inhibitor in 1 patient and to a nucleoside reverse transcriptase inhibitor and a proteas
27 e advent of newer PIs, second-generation non-nucleoside reverse transcriptase inhibitors and drugs in
29 inhibitors in the cART regimen, in favor of nucleoside reverse transcriptase inhibitors and integras
30 was classified as moderate (5%-15%) for both nucleoside reverse-transcriptase inhibitors and nonnucle
31 side reverse transcriptase inhibitors, a non-nucleoside reverse transcriptase inhibitor, and a ritona
32 nevirapine resistance, background regimen of nucleoside reverse-transcriptase inhibitors, and the sta
33 nucleoside reverse transcriptase inhibitor-, nucleoside reverse transcriptase inhibitor-, and proteas
34 nsitivity score </=2 in 10 patients included nucleoside reverse transcriptase inhibitors associated w
35 We found similar proportions of overall and nucleoside reverse transcriptase inhibitor-associated mi
36 One participant in the atazanavir group had nucleoside reverse transcriptase inhibitor-associated re
38 e first time implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated to
39 The addition of the nucleoside reverse transcriptase inhibitor azidothymidin
40 higher risk of virologic failure with either nucleoside reverse transcriptase inhibitor backbone than
41 d safety to a boosted darunavir regimen with nucleoside reverse transcriptase inhibitor background tr
43 .04, 95% CI 1.01-1.07), being prescribed non-nucleoside reverse transcriptase inhibitor-based regimen
44 observed in patients exposed to various non-nucleoside reverse transcriptase inhibitor drugs (NNRTIs
45 drug resistance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has bee
46 were on two ART regimens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or rit
48 ed the use of amdoxovir for the treatment of nucleoside reverse transcriptase inhibitor-experienced p
50 d patients with a protease inhibitor and two nucleoside reverse transcriptase inhibitors failed to re
51 active anti-retroviral therapy with multiple nucleoside reverse transcriptase inhibitors for the trea
52 o received efavirenz, nelfinavir, and 1 or 2 nucleoside reverse-transcriptase inhibitors for > or =2
53 were not observed with other non-allergenic nucleoside reverse transcriptase inhibitors, identifying
54 of these 39 youth, identified resistance to nucleoside reverse transcriptase inhibitors in 62%, nonn
55 ng of efavirenz, nelfinavir, and one or more nucleoside reverse-transcriptase inhibitors in 57 childr
56 ens during pregnancy, 1 of which was without nucleoside reverse transcriptase inhibitors, infants had
57 mutation involved in clinical failure of non-nucleoside reverse transcriptase inhibitors, K103N, and
60 ase (RNAP) "switch region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) bindi
61 ically labeled RT in the presence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavi
62 s) by viruses under the treatment with a non-nucleoside reverse transcriptase inhibitor (NNRTI) in ce
63 with a protease inhibitor (PI) versus a non-nucleoside reverse transcriptase inhibitor (NNRTI) is un
64 NRTI, mainly abacavir+lamivudine) with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or 3
65 have neuropsychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or wh
66 -spectrum antiviral activity against key non-nucleoside reverse transcriptase inhibitor (NNRTI) relat
67 AAP-BHAPs possess the ability to inhibit non-nucleoside reverse transcriptase inhibitor (NNRTI) resis
68 scale-up attributable to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resis
69 ranscriptase inhibitor [NRTI]; n=470), a non-nucleoside reverse transcriptase inhibitor (NNRTI) strat
70 -ci nnamylphenyl)]azo (KM-1)) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that
73 reatment with a protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or b
78 gue (lamivudine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevir
79 ce and practice regarding the use of the non-nucleoside reverse transcriptase inhibitors (NNRTI) efav
80 e substantial increases in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) in e
82 tion, we evaluated the impact of several non-nucleoside reverse transcriptase inhibitors (NNRTI; Efav
83 is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resis
84 ined switching of ART as a change from a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based
85 /diarylpyrimidine (DATA/DAPY) classes of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and
86 erse-transcriptase inhibitors (NRTIs), 4 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and
89 The alkenyldiarylmethane (ADAM) HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are
92 een employed in the synthesis of several non-nucleoside reverse transcriptase inhibitors (NNRTIs) in
93 erent prevalence levels of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) mea
94 antiretroviral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) mig
95 )-quinazolinones were found to be potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) of
97 ylmethanes (ADAMs) are a unique class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) tha
99 d identification of a clinical candidate non-nucleoside reverse transcriptase inhibitors (NNRTIs) wit
100 y-pyridin-2(1H)-ones were synthesized as non-nucleoside reverse transcriptase inhibitors (NNRTIs), an
101 Recently, the use of HIV-1 specific non-nucleoside reverse transcriptase inhibitors (NNRTIs), in
102 the enzyme, is influenced by mutations, non-nucleoside reverse transcriptase inhibitors (NNRTIs), nu
103 elopments within the class of allosteric non-nucleoside reverse transcriptase inhibitors (NNRTIs).
104 eteroaryl)piperazine (AAP-BHAP) class of non-nucleoside reverse transcriptase inhibitors (NNRTIs).
105 Here, we assessed the ability of nucleoside reverse-transcriptase inhibitor/nonnucleoside
106 ir disoproxil fumarate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbo
107 zanavir or ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbo
108 disoproxil fumarate (FTC/TDF) is a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbo
109 iduals initiated ART consisting of different nucleoside reverse transcriptase inhibitor (NRTI) backbo
110 gue mutations (47% vs 18%), all P = .01; and nucleoside reverse transcriptase inhibitor (NRTI) cross-
112 nts were analyzed separately from those with nucleoside reverse transcriptase inhibitor (NRTI) experi
113 and lamivudine or emtricitabine plus another nucleoside reverse transcriptase inhibitor (NRTI) in fix
114 ate reports of greater emergence of the K65R nucleoside reverse transcriptase inhibitor (NRTI) mutati
115 The most frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutati
116 en drug naive patients who were started on a nucleoside reverse transcriptase inhibitor (NRTI) plus a
117 e RNA degradation plays an important role in nucleoside reverse transcriptase inhibitor (NRTI) resist
118 lation of multiple mutations associated with nucleoside reverse transcriptase inhibitor (NRTI) resist
120 A (</=100,000 or >100,000 copies per mL) and nucleoside reverse transcriptase inhibitor (NRTI) select
121 combination ART, and 20 (6.8%) started dual nucleoside reverse transcriptase inhibitor (NRTI) therap
123 When MTS-p53 cells were treated with the nucleoside reverse transcriptase inhibitor (NRTI), 2',3'
124 ve patients, HIV-positive patients receiving nucleoside reverse transcriptase inhibitor (NRTI)-based
125 he ATP-based excision reaction that unblocks nucleoside reverse transcriptase inhibitor (NRTI)-termin
127 ty (6) having the K103N mutation; 2 (4%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutati
128 tease (PR) inhibitor mutations; 41 (91%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutati
129 ompared in men and women initiating a triple nucleoside reverse-transcriptase inhibitor (NRTI) regime
130 except in the presence of the Q151M multiple nucleoside reverse-transcriptase inhibitor (NRTI)--resis
131 vir (ATV/RTV) alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)-sparin
132 a protease inhibitor (PI) strategy (PI plus nucleoside reverse transcriptase inhibitor [NRTI]; n=470
133 ed abacavir, zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibitor [NRTI] group)
134 divided into two classes: nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and N
135 eive a protease inhibitor-sparing regimen of nucleoside reverse transcriptase inhibitors (NRTIs) + ef
137 ed VF on a first-line regimen of PI/r plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) and
139 ts aged >/=18 years who started ART with two nucleoside reverse transcriptase inhibitors (NRTIs) and
145 r oral efavirenz 600 mg once a day with dual nucleoside reverse transcriptase inhibitors (NRTIs) for
146 lthymidine (Ed4T), have been investigated as nucleoside reverse transcriptase inhibitors (NRTIs) for
147 iral recombination and our observations that nucleoside reverse transcriptase inhibitors (NRTIs) incr
149 A major pathway for HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) invo
150 itonavir, lopinavir, and atazanavir) but not nucleoside reverse transcriptase inhibitors (NRTIs) or n
151 mal initial regimens for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus
153 ealth Organization method to classify TDR to nucleoside reverse transcriptase inhibitors (NRTIs), non
155 hare many of the same resistance pathways to nucleoside reverse transcriptase inhibitors (NRTIs).
160 T) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in s
161 phase II dose-finding study of VCV plus dual nucleoside reverse-transcriptase inhibitors (NRTIs) in t
162 er efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is r
164 ase inhibitor (PI) plus nevirapine or with 3 nucleoside reverse-transcriptase inhibitors (NRTIs) plus
165 ver the standard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) seco
167 1 strains to 12 HIV-1 inhibitors including 6 nucleoside reverse-transcriptase inhibitors (NRTIs), 4 n
168 e different sets of mutations in response to nucleoside reverse-transcriptase inhibitors (NRTIs).
169 y virus (HIV) therapy includes a backbone of nucleoside reverse-transcriptase inhibitors (NRTIs).
170 se inhibitor, with adjustment of one or more nucleoside reverse-transcriptase inhibitors (NRTIs).
171 nhibitors, reverse transcriptase inhibitors (nucleoside reverse transcriptase inhibitors [NRTIs] and
172 y virus (HIV) viremia despite treatment with nucleoside reverse-transcriptase inhibitors (nucleoside
173 ity in vitro against wild-type HIV-1 and non-nucleoside reverse transcriptase inhibitor-, nucleoside
176 of treatment with protease inhibitors or non-nucleoside reverse transcriptase inhibitors (OR, 1.29 [C
178 re composed of a first-line regimen of a non-nucleoside reverse transcriptase inhibitor plus two NtRT
180 tic of noncooperative reactions, whereas non-nucleoside reverse transcriptase inhibitors, protease in
181 the 48-week efficacy of a twice-daily triple nucleoside reverse-transcriptase inhibitor regimen conta
182 HIV-1 reverse transcriptases containing non-nucleoside reverse transcriptase inhibitor resistance mu
184 ansmission and the presence of either AZT or nucleoside reverse-transcriptase inhibitor resistance-as
185 possesses the ability to inhibit NNRTI (non-nucleoside reverse transcriptase inhibitor) resistant re
186 WT) HIV-1 reverse transcriptase (RT) and the nucleoside reverse transcriptase inhibitor-resistant mut
187 is notion were (1) the presence of low level nucleoside reverse-transcriptase inhibitor-resistant hum
188 8.8% having resistance to 1 or more NNRTI or nucleoside reverse transcriptase inhibitors, respectivel
189 both alone, and in combination with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
190 (IC(50)s and IC(90)s, respectively) of five nucleoside reverse transcriptase inhibitors (RTIs) were
191 tion of HIV-1 transmission and/or for use in nucleoside reverse transcriptase inhibitor-sparing antir
192 iptase inhibitors (NRTIs) + efavirenz, a non-nucleoside reverse transcriptase inhibitor-sparing regim
193 troviral therapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir.
194 ritonavir-boosted protease inhibitor plus 2 nucleoside reverse transcriptase inhibitors (tenofovir/e
196 ylmethanes (ADAMs) are a unique class of non-nucleoside reverse transcriptase inhibitors that have po
197 ucitabine, Racivir, Reverset and SPD 754 are nucleoside reverse transcriptase inhibitors that were de
198 ed children who were previously treated with nucleoside reverse-transcriptase inhibitors, the combina
199 died in 387 subjects receiving either stable nucleoside reverse transcriptase inhibitor therapy or no
200 als, particularly among those with mono/dual nucleoside reverse transcriptase inhibitor therapy prior
201 rranted to elucidate potential mechanisms of nucleoside reverse-transcriptase inhibitor toxicities.
202 cleoside reverse-transcriptase inhibitor and nucleoside reverse-transcriptase inhibitor transmitted d
203 of the associations between single and dual nucleoside reverse-transcriptase inhibitor use and possi
204 egarding cardiovascular (CV) toxicity of the nucleoside reverse-transcriptase inhibitors used to trea
205 known resistance-conferring mutations to any nucleoside reverse transcriptase inhibitors was found in
208 he combination of efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors was generall
209 europathy during antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previous
210 itonavir and efavirenz, were open-label; the nucleoside reverse transcriptase inhibitors were prematu
211 of glutamate or peptide scaffolds containing nucleoside reverse transcriptase inhibitors were synthes
212 5, nevirapine (200 mg 2x/day) was added, and nucleoside reverse-transcriptase inhibitors were changed
213 adults receiving protease inhibitors or non-nucleoside reverse transcriptase inhibitors who were mon
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。